Organon & Co. — Q1 2024 Form 10-Q
Business context and period. Global healthcare company focused on women’s health, biosimilars and established brands, with more than 60 medicines and products. This unaudited report covers the three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. Organon reports one operating segment.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / comparison |
|---|---|---|
| Revenue | $1.622 billion | $1.538 billion; up 5% reported and 7% excluding FX |
| Gross profit and margin | $957 million; 59.0% | $958 million; 62.3% |
| Income before taxes | $236 million | $235 million |
| Net income | $201 million | $177 million |
| Diluted EPS | $0.78 | $0.69 |
| Operating cash flow | $76 million | $114 million |
| Investing / financing cash flow | $(96) million / $(74) million | $(54) million / $(326) million |
Cash and cash equivalents were $575 million at quarter-end, down from $693 million at December 31, 2023. Working capital was $1.7 billion, versus $1.6 billion at year-end. Total principal debt was $8.714 billion ($8.705 billion long-term debt, net of current portion); weighted-average borrowing rate was 5.7%, and average maturity was approximately 4.7 years. The company reported compliance with debt covenants and no default. The largest scheduled principal payment is $6.755 billion in 2028.
Material changes and operating drivers
- Revenue growth was led by Nexplanon/Implanon NXT ($220 million, up 33%), Hadlima ($30 million versus $5 million), Ontruzant ($39 million, up 86%) and recovery in Diprospan ($29 million, up 103%). Hadlima benefited from its U.S. launch in July 2023; Ontruzant benefited from a Brazil government tender; Diprospan recovered from prior manufacturing issues.
- Offsets included declines in Singulair (down 18%), Cozaar/Hyzaar (down 21%), NuvaRing (down 22%) and Follistim AQ (down 17%). NuvaRing faced generic competition; Cozaar/Hyzaar were affected by China’s volume-based procurement program. FX reduced quarterly sales by approximately $30 million.
- Cost of sales rose 15% to $665 million, outpacing revenue growth, due primarily to higher sales, unfavorable mix, FX translation and inflation in material and distribution costs. SG&A declined 1% to $431 million; R&D declined 13% to $112 million.
- Effective tax rate fell to 14.7% from 24.6%, primarily reflecting the favorable closure of two non-U.S. tax audits. Net income increased despite nearly flat pretax income.
- Operating cash flow fell to $76 million, mainly due to working-capital movements, including a $349 million reduction in trade accounts payable. Investing cash outflow included a $50 million upfront payment for European distribution rights to Lilly’s Emgality and Rayvow; Organon recognized a $220 million intangible asset, including $170 million of probable sales-based milestones.
Outlook, risks and unusual items
- The filing gives no specific revenue or earnings guidance. Management expects positive operating cash flow and believes financing arrangements, future operating cash flow and capital-market access will support future needs. It expects higher cash taxes in 2024 than in 2023 and expects China VBP to continue affecting established-brand sales for several quarters.
- Organon expects continued NuvaRing sales decline from generic competition and anticipates Atozet loss of exclusivity in certain European markets beginning in Q3 2024. It expects Diprospan’s sales recovery to continue during 2024.
- Restructuring expense was $23 million in Q1. Combined restructuring activities are expected to reduce headcount by approximately 5% by year-end 2024; remaining severance payments are expected over the next 12 months.
- Organon plans to separate and optimize its manufacturing and supply network, including planned exits from Merck supply agreements through 2031. Expected costs may include exit fees, technology transfers, qualification batches, regulatory work, capital investment and inventory bridging.
- Contingencies include litigation and indemnification obligations. Approximately 3,125 Fosamax femur-fracture cases were pending against Merck, with Organon potentially required to indemnify Merck under the separation agreement. Organon has no insurance for most product-liability exposures and says it cannot reasonably estimate possible losses for certain matters. The Nexplanon patent dispute was settled in December 2023; $35 million was paid and $45 million reserved for the remainder.
- Other risks include pricing and reimbursement pressure, generic competition, product-development and commercialization execution, supply reliability and costs, foreign-exchange exposure, and variable-rate debt exposure. The company has no interest-rate hedges. Management reported effective disclosure controls; ERP general-ledger implementation remained in progress and was expected to be completed in Q2 2024.
Investor verification priorities
- Track whether sales growth persists after adjusting for FX, distributor buying patterns and tender timing, and monitor product-level exposure to generic competition and China VBP.
- Assess whether gross-margin pressure and working-capital outflows persist, particularly the reduction in payables and the resulting effect on operating cash generation.
- Review debt service and refinancing risk ahead of the substantial 2028 maturities, alongside cash needs for dividends, supply-chain separation and strategic transactions.
- Monitor the realization and amortization of the $220 million Lilly-related intangible asset, including whether the $170 million of probable milestones become payable.
- Follow litigation developments, indemnification exposure, the remaining Nexplanon settlement payments, and the adequacy of legal reserves.
- Verify 2024 cash-tax expectations, restructuring savings and costs, and completion of the ERP general-ledger implementation.